A Pilot Randomized, Open Label Trial of Orexin Receptor Antagonist for Insomnia in Hospitalized Patients With Cancer to Prevent Delirium
Latest Information Update: 09 May 2025
At a glance
- Drugs Suvorexant (Primary)
- Indications Delirium; Insomnia
- Focus Therapeutic Use
Most Recent Events
- 01 May 2025 Status changed from recruiting to withdrawn prior to enrolment due to low/slow accrual
- 10 Mar 2025 Status changed from not yet recruiting to recruiting.
- 27 Feb 2025 New trial record